Number of first serious infections by infection site
| All patients (n=2356) | Etanercept (n=959) | Adalimumab (n=776) | Infliximab (n=621) | |
|---|---|---|---|---|
| Any serious infection (N (%)) | 125 (5.3) | 31 (3.2) | 43 (5.5) | 51 (8.2) |
| Site of infection (N (%)) | ||||
| Lower respiratory tract | 45 (36) | 9 (29) | 15 (34.9) | 21 (41.2) |
| Skin and soft tissue | 22 (17.6) | 5 (16.1) | 9 (20.9) | 8 (15.7) |
| Musculoskeletal | 13 (10.4) | 3 (9.7) | 5 (11.6) | 5 (9.8) |
| Upper respiratory tract | 12 (9.6) | 6 (19.4) | 3 (6.9) | 3 (5.9) |
| Cardiovascular | 9 (7.2) | 4 (12.9) | 3 (6.9) | 2 (3.9) |
| Intra-abdominal | 8 (6.4) | 1 (3.2) | 4 (9.3) | 3 (5.9) |
| Urinary tract | 6 (4.8) | 2 (6.5) | 1 (2.3) | 3 (5.9) |
| Other | 6 (4.8) | 0 (0) | 2 (4.7) | 4 (7.8) |
| Ear, nose, throat | 2 (1.6) | 1 (3.2) | 0 (0) | 1 (2.0) |
| Sepsis | 2 (1.6) | 0 (0) | 1 (2.3) | 1 (2.0) |